Diabetes is a lifelong chronic disease
caused by excessive levels of glucose in the blood mainly due to lack or
insufficiency of insulin hormone to metabolize the glucose in the
blood. This accumulated glucose level in the blood does not reach body
cells and severely affects multiple organs such as kidneys, eyes,
nerves, blood vessels, and heart. Diabetic Retinopathy is one of the
common diabetic eye diseases characterized by the damaged blood vessels
in the retina. The damaged blood vessels and nerves lead to blurring of
vision, vision impairment, and eye hemorrhage. If left untreated, it may
lead to retinal detachment and blindness. Non Proliferative Diabetic
Retinopathy (NDPR) and Proliferative Diabetic Retinopathy (PDR) are the
two stages of diabetic retinopathy. Diabetic retinopathy can be treated
through medicines, laser surgery, and vitrectomy. Diabetic retinopathy
can develop in any individual suffering from type 1 or type 2 diabetes.
This disease is the leading cause of blindness in the U.S.
Increase in prevalence of diabetes across
the globe is anticipated to drive the diabetic retinopathy market.
According to National Center for Biotechnology Information, 126 million
people were affected by diabetic retinopathy in 2010; more than 191
people are likely to be affected by Diabetic retinopathy by 2030.
According to the American National Health and Nutrition Examination
Survey conducted between 2005 and 2008, 28.5% of diabetic patients had
some degree of DR, while 4.4% of patients suffered from vision
threatening diabetic retinopathy. Increase in geriatric population, high
prevalence of obesity, and rise in sedentary lifestyle are the key
factors driving the global diabetic retinopathy market. Furthermore,
increase in awareness about the early detection of Diabetic retinopathy
among diabetic patients across the globe, rise in healthcare facilities
in emerging and developed countries, and availability of multiple
treatment options with advanced technology are the factors propelling
the market. However, negligence of Diabetic retinopathy, poor planning
of Diabetic retinopathy treatment in low income countries, and lack of
skilled professionals for treatment of Diabetic retinopathy in emerging
and less developed countries are the key restraining factors of the
market.
The global diabetic retinopathy market
can be segmented based on stages of diabetic retinopathy, type of
treatment, end-user, and region. There are primarily two stages of
diabetic retinopathy: Non proliferative diabetic retinopathy (NPDR) and
Proliferative Diabetic Retinopathy (PDR). NPDR is early stage of
Diabetic retinopathy characterized by the leakage of blood vessels,
resulting in deposition of blood and blood components in retina. PDR is
the advanced stage of Diabetic retinopathy characterized by abnormal
growth of blood vessel, which results in swelling of retina called
Diabetic Macular Edema (DME). Diabtetic retinopathy can be treated and
controlled through injections of Vascular Endothelial Growth Factor
(VEGF), laser treatments, and vitrectomy. Laser treatment is further
classified into focal laser treatment and scattered laser treatment.
In terms of geography, the global
diabetic retinopathy market can be divided into North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. North America
is expected to dominate the market during the forecast period owing to
the rise in prevalence of diabetic retinopathy patients in the region,
increase in healthcare infrastructure, and growth in awareness about
Diabetic retinopathy among diabetic patients. Asia Pacific is estimated
to follow North America, led by the increase in diabetic population and
changing lifestyle of people in the region. Asia Pacific is expected to
maintain the highest growth rate during the forecast period. Middle East
& Africa is projected to be the least attractive market primarily
due to the presence of low income groups, lack of skilled professionals,
and poor accessibility to healthcare facilities in the region.
Key players operating in the global
diabetic retinopathy market are ThromboGenics N.V., F. Hoffmann-La Roche
Ltd, Bayer AG, Novartis AG., Allergan Inc., Abbott Laboratories Inc.,
Pfizer Inc., and Valeant Pharmaceutical International, Inc. New business
development through acquisitions and mergers, and establishment of
subsidiaries in emerging economies are some of the common trends
observed in the global diabetic retinopathy market.
No comments:
Post a Comment